Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management.

doi:10.1002/ajh.70395

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management.

American journal of hematology - 1 Sept 2026

Pardanani Animesh

Abstract excerpt

OVERVIEW: Systemic mastocytosis (SM) results from clonal proliferation of mast cells (MC) in extra-cutaneous organs. DIAGNOSIS: The major criterion is the presence of multifocal MC clusters in the bone marrow and/or extracutaneous organs. Minor diagnostic criteria include elevated serum tryptase level, MC CD25/CD2/CD30 expression, and the presence of activating KIT mutations. RISK STRATIFICATION: Establishing SM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Management
Share to Mast Cells
Share to Mastocytosis, Systemic
Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 42310859
DOI: 10.1002/ajh.70395
PMCID: PMC13428365

Genes

AMN
KIT
ASXL1
CD2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management.

Abstract excerpt

Topics

Provenance